| Fiscal Period | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Period End Date | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
| Total Operating Expense | 2,058.36 | 1,994.02 | 700.00 | 821.52 |
| Other Net | 34.09 | 69.21 | 6.35 | 3.40 |
| Diluted Weighted Average Shares | 38.30 | 38.43 | 25.46 | 25.46 |
| Depreciation/ Amortization | 187.33 | 166.80 | 54.50 | 47.73 |
| Operating Income | 210.19 | 614.48 | 351.35 | 518.81 |
| Net Income | 179.23 | 487.34 | 300.28 | 411.29 |
| Income Availableto Com Excl Extra Ord | 179.23 | 487.34 | 300.28 | 411.29 |
| Other Operating Expenses Total | 671.22 | 547.15 | 50.00 | 61.91 |
| Net Income Before Taxes | 207.04 | 642.63 | 405.67 | 559.73 |
| Minority Interest | 29.11 | 3.10 | - | - |
| Net Income After Taxes | 150.12 | 484.24 | 300.28 | 411.29 |
| Income Availableto Com Incl Extra Ord | 179.23 | 487.34 | 300.28 | 411.29 |
| Costof Revenue Total | 662.63 | 816.48 | 432.62 | 568.34 |
| Gross Profit | 1,605.92 | 1,792.02 | 618.73 | 771.99 |
| Interest Inc( Exp) Net- Non- Op Total | -37.24 | -41.06 | 48.10 | 37.53 |
| Unusual Expense( Income) | 29.47 | 15.78 | 3.22 | - |
| Diluted Net Income | 179.23 | 487.34 | 300.28 | 411.29 |
| Provisionfor Income Taxes | 56.92 | 158.39 | 105.39 | 148.44 |
| period Type | - | - | - | - |
| Net Income Before Extra Items | 179.23 | 487.34 | 300.28 | 411.29 |
| Total Revenue | 2,268.55 | 2,608.50 | 1,051.35 | 1,340.33 |
| period Length | 12.00 | 12.00 | 12.00 | 12.00 |
| Revenue | 2,268.55 | 2,608.50 | 1,051.35 | 1,340.33 |
| Selling/ General/ Admin Expenses Total | 507.71 | 447.81 | 159.66 | 134.95 |
| Diluted Normalized EPS | 5.24 | 12.99 | 11.89 | 16.16 |
| Diluted EPS Excluding Extra Ord Items | 4.68 | 12.68 | 11.80 | 16.16 |
| Total Adjustmentsto Net Income | - | - | 0.00 | - |
| Gain( Loss)on Saleof Assets | - | - | -0.14 | -0.01 |
| DPS- Common Stock Primary Issue | - | - | - | 1.00 |
| Research Development | - | - | - | 8.59 |
Cohance Lifesciences Dividend Cohance Lifesciences Bonus Cohance Lifesciences News Cohance Lifesciences AGM Cohance Lifesciences Rights Cohance Lifesciences Splits Cohance Lifesciences Board Meetings Cohance Lifesciences Key Metrics Cohance Lifesciences Shareholdings Cohance Lifesciences Balance Sheet Cohance Lifesciences Cashflow Cohance Lifesciences Q1 Results Cohance Lifesciences Q2 Results Cohance Lifesciences Q3 Results Cohance Lifesciences Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.